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LETTERS TO THE EDITOR 
The benefit of heparin-bound circuits 
To the Editor: 
We read with interest he recently published paper by 
Gorman and associates I on surface-bound heparin in 
extracorporeal circuits. The study was well conceived and 
conducted. Several questions remain, however. The first 
question concerns the appropriateness of including sev- 
eral of the patients in the study. Four of the 20 patients, 
two in each group, underwent pulmonary arterial throm- 
bectomy. Circulatory arrest of relatively long duration was 
applied in all, and at low body temperatures, varying from 
12 ° to 14.9 ° C. Extreme hypothermia can result in severe 
disturbances in coagulation) The prolonged circulatory 
arrest in these patients suggests the presence of great 
quantities of thrombotic material. If these thrombi had 
been recently formed--and this was not stated in the 
paper--they may have resulted in significant consumption 
of coagulation factors. In our opinion these three patients 
should not have been included in the study. 
Second, the authors state that a Cell Saver System 
(Haemonetics, Braintree, Mass.), was used in all patients, 
implying extensive contact between blood and uncoated 
synthetic material. Washing blood with normal saline 
solution results in removal of plasma, which would also 
greatly affect coagulation. In addition, no mention was 
made of how much blood per patient was so treated. 
Third, experimental nd clinical studies have shown 
that heparin-coated circuits yield some attenuation of 
inevitable damage to blood components, but that the 
difference wit]h uncoated circuits is slight. We were there- 
fore surprised that the study's conclusions correspond 
entirely with those of our animal experimental re- 
search,3, 4 despite the possible shortcomings of the meth- 
ods. Our study used a venovenous coated or uncoated 
circuit with low flow in unheparinized ogs. We, too, 
found some protection of circulating blood by coated 
circuits, and we also found no reduction in blood coagu- 
lability. We therefore agree with the authors' conclusion 
that reducing the dose of heparin when a heparin-coated 
system is used, as is advocated by some, 5 is unwise and 
even dangerous. 
Adrian C. Moulijn, MD, PhD 
Brain J. Amsel, MD 
Department of Cardiac Surgery 
University Hospital of Antwerp 
Edegem, Belgium 
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Reply to the Editor." 
We appreciate Drs. Moulijn and Amsel's interest in our 
study and are happy to clarify the points raised that may 
also have concerned others. The patients were consecutive 
to reduce any possibility of bias. The patients with pulmo- 
nary thromboendarterectomy were included primarily to 
permit the heparin-coated circuits to demonstrate their 
benefits, if any, by increasing the duration of perfusion 
and therefore blood trauma. The prothrombin fragment 
F1.2 measurements at the end of cardiopulmonary b pass 
for the four patients having thromboendarterectomy were 
6.22, 5.63, 5.19, and 5.51 mmol/L. Data from these four 
patients did not exceed the range of the other patients at 
any time for any variable studied. In addition, statistical 
analysis of the data after exclusion of these patients did 
not change our results or conclusions. Concern that these 
patients' pulmonary teries contained large quantities of 
fresh thrombus that "resulted in significant consumption 
of coagulation factors" is unfounded. All these patients 
had the syndrome of chronic pulmonary thromboembo- 
lism. 
The lack of heparin coating on the Cell Saver System 
(Haemonetics, Braintree, Mass.) is irrelevant o the hy- 
pothesis tested. The same system was used in both groups 
and only packed red blood cells were returned to the 
patients. Any coagulation factors activated by contact with 
the Cell Saver System would have been discarded before 
reinfusion. 
We are sorry that Drs. Moulijn and Amsel find short- 
comings in our methodology. In defense, we point out that 
a large number of quantitative measurements of platelet, 
neutrophil, and plasma protein activation were assessed. 
Although we found that heparin coatings increase adsorb- 
tion of antithrombin III, affect complement activation, 
and increase platelet and monocyte adhesion, we did not 
demonstrate an anticoagulant effect. 
The results of our study, Wagner's tudy, Moulijn and 
Amsel's study, and an increasing number of others concur 
that heparin-coated perfusion circuits do not reduce 
thrombin formation or activity. The use of these circuits 
without full systemic heparization subjects patients to the 
increased risk of thromboembolic complications associ- 
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